arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Korro Bio, Inc.

KRRO
$13.22 ▲ +1.04 (+8.54%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
25 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Korro Bio, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $153.3M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC None
FCF / Share $-1.39
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-19.62M
↑ +16.1%
Operating Margin Operating profit as % of sales
-185.7%
↑ +57.3%
FCF / Share Free cash flow per share
$-1.39
↑ +47.0%
Long-Term Debt Long-term obligations
$180.00K
↓ -18.9%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.67x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters